Johnson & Johnson has begun clinical trials for an Ebola vaccine in Sierra Leone.» Read More
The Ebola epidemic in West Africa could infect 20,000 people, warning that an international effort costing almost half a billion dollars is needed.
The trials will start at the NIH in Maryland. A vaccine is "the first step in a long process" to control Ebola, Dr. Anthony Fauci says. NBC reports.
Nearly 20 percent of all U.S. states are eyeing the possibility of adopting technology from Connecticut's lauded health insurance marketplace.
American investors aren't panicked about the re-emergence of Ebola in Africa, at least in the long term.
Mobile internet is China's most lucrative sector according to Fosun International, the country's largest private investment firm.
The economic cost of cardiovascular disease in Europe is set to increase to around $162 billion annually by 2020, a new report has found.
The emerging field of big data analytics can play a role for couples trying to have a baby or avoid it, says Silicon Valley pioneer Max Levchin.
A federal watchdog has issued subpoenas in its probe of Maryland's troubled health insurance exchange.
The stratospheric rise of vaping may be halted by increasing regulation.
Kevin Counihan, who spent two years running Access Health CT, becomes the first person whose sole responsibility is running HealthCare.gov.
The public is paying hundreds of millions of dollars in hospital costs for gunshot victims who lack private insurance, according to a new study.
Nigeria's health minister has insisted the Ebola outbreak has been contained in the country.
The potential for Pfizer to take over AstraZeneca has sent its prey’s share price soaring and caused political ructions on both sides of the Atlantic.
The number of compensation claim applications as the result of a deadly defect GM ignored has reached 100.
The Department of Veterans Affairs promised sweeping changes and ample contrition in prepared remarks to an inspector general's. USA Today reports.
CNBC.com's health care reporter Dan Mangan provides insight to a potential tax surprise for some recipients of Obamacare.
Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.
Medicare’s five-year-old rating system to help families select nursing homes relies on unverified, incomplete and often misleading data. The NYT reports.
Pediatricians have a new prescription for schools: later start times for teens.
Biotech firm Roche announced plans Sunday to buy InterMune for $8.3 billion on a fully diluted basis in an all-cash transaction.
Get the best of CNBC in your inbox